Re your comment on generics saving lives, yea, this is a pickle question between sovereigns in negotiating trade agreements. The US pharmaceutical behemoths make too much money in my opinion. The inability of Medicare to negotiate on drug pricing was an insane give away from Bush that effectively allows drug companies the ability to set their desired profit targets. But with other nations catching up in terms of Quality and manufacturing tech transfers, most small molecules will be easily riffed. The era of blockbuster small molecules is coming to an end with a lot of the space/targets explored. More complicated biological and gene/cell therapies are the next frontier and it's going to be a lot harder to riff these technologies because "the product is the process" a lot of time. It's a lot harder to steal process without hiring know-how.